Market Overview

Global Pulmonary Arterial Hypertension (PAH) Market Analysis & Outlook 2018-2022 - Four Classes of Drugs Approved and 13 Approved Products are Available -


The "Global
Pulmonary Arterial Hypertension (PAH) Market: Industry Analysis &
Outlook (2018-2022)"
report has been added to's

Global Pulmonary Arterial Hypertension Market: Industry Analysis &
Outlook (2018-2022)
provides an extensive research and detailed
analysis of the present market along with future outlook. The report
discusses the major growth drivers and challenges of the market,
covering The United States and Europe region along with the global

There are currently four classes of drugs approved for the treatment of
PAH and 13 approved products are available for PAH in the market across
these four drug classes.

The United States is the main contributor to the PAH market with the
development of new therapies and increasing cases of pulmonary arterial
hypertension. The U.S. has great potential in the years ahead with
rising awareness about treatment options of PAH.

The global PAH market is expected to grow in the future due to
increasing ageing population, rise in healthcare expenditure, growing
women population, increase in obese population and high unmet needs. Key
trends of this market include increasing number of cardiovascular
diseases, rising government support, and consumption of junk food.
However, there are some factors which can hinder the growth of the
market which includes patent expiration, high cost and lack of awareness.

Key Topics Covered:

1. Market Overview

2. Global Market Analysis

3. Regional Market

4. Market Dynamics

5. Competitive Landscape

6. Company Profiles

  • Johnson & Johnson
  • Gilead Sciences
  • United Therapeutics
  • GlaxoSmithKline

For more information about this report visit

View Comments and Join the Discussion!